Paul Loar, MD
Gynecologic Oncology · Austin, TXNPI 1063488617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $217, more than ten times the $14 reported in 2021. That places this record below the midpoint for gynecologic oncology clinicians in TX, where the typical reported total is $3,034.
Across 27 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$81
- AstraZeneca$68
- AbbVie$67
- GSK$66
- Astellas Pharma US Inc$48
- Myriad Genetic Laboratories, Inc.$48
- plus $222 from 7 others
What the payments were for
- Food & beverage$600100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $81 |
| AstraZeneca | 3 | $68 |
| AbbVie | 3 | $67 |
| GSK | 3 | $66 |
| Astellas Pharma US Inc | 2 | $48 |
| Myriad Genetic Laboratories, Inc. | 3 | $48 |
| Johnson & Johnson | 2 | $46 |
| Eisai Inc. | 2 | $43 |
| Seagen Inc. | 2 | $38 |
| Servier Pharmaceuticals LLC | 1 | $30 |
| Tempus AI, Inc | 1 | $26 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Clovis Oncology, Inc. | 1 | $18 |
How this compares
$600 in reported general payments places this provider in the 15th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 88 | $687 |
| Dexamethasone | 64 | $658 |
| Prochlorperazine Maleate | 52 | $595 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 46 | $531 |
| Ondansetron Hcl | 64 | $275 |
| Letrozole | 11 | $211 |
| Olanzapine | 28 | $106 |
| Gabapentin | 21 | $93 |
| Tramadol Hcl | 17 | $55 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Austin
- Helen EshedAustin$35K
- Priyanka KamathAustin$4K
- Lynne KnowlesAustin$4K
- Robert ColemanHouston$864K
- Reagan StreetFort Worth$280K
- Joseph de la GarzaSan Antonio$234K
- Maurie MarkmanHouston$204K
- Dustin MandersDallas$171K
- Tiffany RedfernFort Worth$165K
- Antonio Santillan-GomezSan Antonio$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.